Litcius/Paper detail

[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab

Romain‐David Seban, Emilie Arnaud, Delphine Loirat, Luc Cabel, Paul Cottu, Lounes Djerroudi, S. Hescot, Pierre Loap, Claire Bonneau, François‐Clément Bidard, Virginie Huchet, Nina Jehanno, Arnaud Berenbaum, Laurence Champion, Irène Buvat

2023European Journal of Nuclear Medicine and Molecular Imaging30 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabBreast cancerChemotherapyOncologyInternal medicineStandardized uptake valueCancerPositron emission tomographyTriple-negative breast cancerRetrospective cohort studyNeoadjuvant therapyStage (stratigraphy)CohortImmunotherapyNuclear medicineBiologyPaleontologyMedical Imaging Techniques and ApplicationsBreast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab | Litcius